Press Release
Clinic Secret 2025 Review: The GLP-1 Weight Loss Platform Behind Ozempic, Semaglutide & Tirzepatide Access From Home
At-home medical service offers streamlined access to GLP-1 prescriptions like Ozempic®, Semaglutide, and Tirzepatide with no insurance requirements or in-person visits. Read More
Press Release
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program
-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record of building and leading high performing operating teams and financing in the capital markets with over $1B+ raised and multiple company exits by acquisition -- CID-103 is a potential best in class, anti-CD38 monoclonal antibody, currently dosing in a multi-center Phase 1/2 study in adults with chronic immune thrombocytopenia (ITP); IND submitted to support future clinical trials in adults with renal allograft antibody-mediated rejection (AMR) Read More
Press Release
Emmy-Nominated Producer Launches Interactive Cold Case Series 'True Crime: Unsolved' on YouTube
The new series empowers audiences to help revive forgotten cold cases through immersive storytelling, firsthand accounts, and direct access to active investigations in hopes of sparking new leads and finding justice for overlooked victims. Read More
Press Release
CORRECTION FROM SOURCE: Cytta Corp to Report Marketable Securities in Excess of $6,000,000 in Delayed March 31, 2025, 10-Q
Correction to the number of shares in the first paragraph Upon Completion of the 10-Q Quarterly Interim Review filing, Cytta Corp will be Current and Will Regain OTCQB Status Read More
Press Release
